Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + SOX Perioperative Treatment for Resectable Locally Advanced Gastric/GEJ Adenocarcinoma
NCT06766305Phase 2Recruiting
- Start
- Mar 2025
- Primary completion
- Feb 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma. Primary endpoints: Dose-limiting toxicity at 21 days, Recommended Phase II Dose at 21 days and 1 more. Started Mar 2025; status: recruiting.
02
Drugs
QL1706
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06766305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06766305.